SecBot SecBot
SC 13G ·Filed Oct 22, 2026

CTNM

Contineum Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed4d 2h ago SEC0001493152-26-048104
Passive investor 5%+ stake
Actionable Insight • Neutral

Monitor for any future conversion to a 13D filing, which would signal activist intent. For now, this is a routine passive disclosure with no immediate trading catalyst.

DirectionNeutral
Confidencehigh
Horizonweeks
Latest settled — T+1d
CTNM ▼ -2.05% at T+1d
NEUTRAL call -2.05% · α vs SPY -2.76% · entry $8.31 → $8.14
Next anchor: T+5d in 3d
Entry = T+0 close
Oct 22, 2026
via day close
T+1d
-2.05%
call -2.05% · α -2.76%
$8.14
settled 3d ago
T+5d
Pending
in 3d
T+20d
Pending
in 24d
T+60d
Pending
in 3mo

Price Chart

Loading chart...

Executive Summary

Trails Edge Capital Partners, LP and related entities filed a Schedule 13G disclosing a 5.1% passive stake in Contineum Therapeutics, Inc. as of September 22, 2026. The filing certifies no intent to influence control, indicating a routine passive investment.

Key Financial Metrics

Stake
5.1%
Investor
Trails Edge Capital Partners, LP
Investor Type
hedge fund

Key Facts

  • Trails Edge Biotechnology Master Fund, LP holds 1,679,443 shares of Class A Common Stock directly.
  • The stake represents 5.1% of outstanding shares based on 32,958,632 shares outstanding as of July 24, 2026.
  • Filers include Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai.
  • The filing is under Rule 13d-1(c), confirming passive intent with no control influence.
  • This is a new 13G filing (not an amendment), indicating a new 5%+ position.

Financial Impact

5.1% passive stake valued at approximately $1.68 million based on share count; no transaction value disclosed.

ownership_percentage

Risk Factors

  • Potential future conversion to 13D if the investor's intent changes.
  • No information on cost basis or future buying/selling plans.

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G Filing (Primary)0001493152-26-048104
Document: 0001493152-26-048104-index-headers.html0001493152-26-048104
Document: 0001493152-26-048104-index.html0001493152-26-048104
Document: 0001493152-26-048104.txt0001493152-26-048104
6 reports for CTNM
Performance horizon
Filters
Rows
Reports for CTNM — sortable, filterable
TypeNow
Oct 22, 2026
4d ago
SC 13G
NEUTRAL ★ 3/10
$8.31awaiting T+20—$8.14 (−2.05%)
Sep 22, 2026
4w ago
Institutional Cluster
MIXED ★ 3/10
$13.40 $8.46▼ −36.87%▼ −36.31%$8.14 (−39.25%)
Jul 8, 2026
15w ago
Insider Cluster
NEUTRAL ★ 2/10
$15.45 $15.35▼ −0.65%▼ −2.89%$8.14 (−47.31%)
Jul 2, 2026
16w ago
Insider Cluster
NEUTRAL ★ 3/10
$15.53 $15.93▲ +2.58%▲ +1.73%$8.14 (−47.59%)
Jul 1, 2026
16w ago
Insider Cluster
NEUTRAL ★ 2/10
$15.10 $15.75▲ +4.30%▲ +4.72%$8.14 (−46.09%)
Mar 5, 2026
33w ago
8-K
NEUTRAL ★ 5/10
$13.88 $13.44▼ −3.17%▼ −1.13%$8.14 (−41.35%)
Showing 6 of 6

US Market Status

Market Closed — Opens Tue (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 22, 2026